Vaccine and Drug Combination Cuts Melanoma Recurrence by Half
The combination therapy kept 68.8% of patients cancer-free at five years, compared with 49.1% on Keytruda alone, researchers said.
- On Monday, researchers presented data at the American Society of Clinical Oncology conference showing a personalized mRNA vaccine halved the risk of melanoma returning after five years.
- Moderna and Merck developed the personalized vaccine, intismeran autogene, which sequences a patient's tumor DNA to encode up to 34 neoantigens that train T-cells to recognize and attack cancer cells.
- In the 157-patient trial, 68.8% of those receiving combination therapy remained cancer-free after five years, compared with 49.1% for patients treated with Keytruda alone.
- Stage 3 melanoma patient Connie Franciosi, who participated in the trial, reported no recurrence, illustrating the potential for high-risk patients to avoid common relapse rates.
- A larger Phase 3 trial involving 1,000 patients is currently underway, and researchers aim to seek FDA approval in the coming months pending analysis of results.
72 Articles
72 Articles
They are working on a personalized vaccine for melanoma with tempting promises
An experimental personalized vaccine developed by Moderna and Merck has demonstrated remarkable long-term success in preventing the return of deadly melanoma, the most aggressive form of skin cancer. New five-year data from a clinical trial presented Monday at the American Society of Clinical Oncology’s annual meeting reveals that adding the tailored mRNA vaccine to standard […]
Success in developing an mRNA vaccine against skin cancer: According to researchers, the vaccine can reduce the risk of relapse by half.
The Independent
The Independent (US)Breakthrough melanoma vaccine would slash risk of the deadly cancer returning
An estimated 112,000 new melanoma cases and 8,500 deaths are expected this year
Doubts About Meaningfulness: New mRNA Vaccination Halved According to Study Skin Cancer Relapse Risk
A new mRNA therapy against black skin cancer shows seemingly impressive results. It significantly reduces the risk of relapse. However, it remains open whether this can really save lives in the end. In addition, experts warn against the immense costs.
Coverage Details
Bias Distribution
- 43% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
